PIK3CG and breast carcinoma: Plus, trastuzumab, an anti‐HER2 agent, facilitates the expression of HER3 in breast cancer cells, and its overexpression can also activate PI3K/AKT pathway, resulting in resistance to anti‐HER2 therapies [5].